| Trial ID: | L2644 |
| Source ID: | NCT01333592
|
| Associated Drug: |
Kad-1229
|
| Title: |
Long-term Study of KAD-1229 in Type 2 Diabetes Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01333592/results
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: KAD-1229
|
| Outcome Measures: |
Primary: Incidences of Adverse Events, 52 weeks | Secondary: Change From Baseline in HbA1c at 52 Weeks, at week 0 and week 52
|
| Sponsor/Collaborators: |
Sponsor: Kissei Pharmaceutical Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
136
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
|
| Completion Date: |
2012-11
|
| Results First Posted: |
2014-11-24
|
| Last Update Posted: |
2014-12-15
|
| Locations: |
Japan, Kanto region, Chugoku region, Kyushu region, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01333592
|
